Oculis takes second eye disease therapy into pivotal trials Oculis is poised to start registration trials for privosegtor, its drug candidate for neuro-ophthalmic diseases, in the wake of positive phase 2 data.

Swiss #biotech #Oculis is poised to start registration trials for privosegtor, its drug candidate for #neuroophthalmicdiseases, in the wake of encouraging phase 2 data.

pharmaphorum.com/news/oculis-...

Growth Forecast of the Cataract Surgery Complications Market Up to 2034 The cataract surgery complications market is set to see significant growth driven by new therapies, improved diagnostics, and increased awareness from 2025 to 2034.

Growth Forecast of the Cataract Surgery Complications Market Up to 2034 #None #VivaVision #cataract_surgery #Oculis